Status:
COMPLETED
Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
Lead Sponsor:
Henry Ford Health System
Conditions:
Prophylaxis
Stem Cell Transplant Complications
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Ciprofloxacin and levofloxacin are both in guidelines to use for prophylaxis in autologous and allogeneic Stem cell transplant.Ciprofloxacin was recently replaced by levofloxacin as the preferred agen...
Eligibility Criteria
Inclusion
- Patients 18-75 years of age with a diagnosis of a hematological malignancy. Meet the stem cell transplant program criteria to undergo autologous or allogeneic hematopoietic stem cell transplantation.
Exclusion
- Prolonged QT
- Allergies to ciprofloxacin or levofloxacin
Key Trial Info
Start Date :
March 14 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2024
Estimated Enrollment :
308 Patients enrolled
Trial Details
Trial ID
NCT03850379
Start Date
March 14 2018
End Date
August 30 2024
Last Update
October 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford
Detroit, Michigan, United States, 48202